Edison Scientific and Population Health Partners Partner to Build the Next Generation of Biotech Companies

Edison Scientific and Population Health Partners (PHP) today announced a strategic partnership to create and launch new biotechnology companies focused on some of the world's largest health challenges.

Under the partnership, Edison and PHP will combine PHP's track record of building successful biotechnology companies with Edison's AI scientist, Kosmos, to identify new opportunities, advance drug programs faster and with greater efficiency, and advance a broader range of innovative new businesses than would be possible through traditional approaches.

PHP is the team behind several notable biotechnology successes, including Metsera, the obesity drug company acquired by Pfizer in a deal worth up to $10 billion, and The Medicines Company, which was acquired by Novartis for $9.7 billion. Population Health Partners focuses on identifying innovations with the potential to improve healthspan at scale, and building companies to advance those innovations with industry-leading efficiency.

Rather than using AI for a single step in the drug development process, Edison and PHP plan to embed Kosmos throughout the lifecycle of ideation, company creation, and drug development — from identifying promising opportunities to dynamically analyzing clinical and nonclinical data, facilitating expert dialogue, and accelerating the development of scientific reports and regulatory deliverables.

The partnership's first effort is already underway and focuses on the full spectrum of development activities around an advanced, clinical-stage asset in PHP’s portfolio with the potential to impact 10% of the world’s population. Additional domains the partners will collaborate on include cardiovascular disease, inflammatory lung disease, and gastrointestinal diseases.

"We've shown that it's possible to build category-defining biotech companies around major population health problems," said Whit Bernard, Managing Partner at Population Health Partners and founder and CEO of Metsera. "The challenge is scale. There are far more important innovation opportunities than any one team can pursue. We believe AI can help us evaluate more opportunities, move faster, and ultimately build many more companies capable of bringing important new medicines to patients."

"Many of the best medicines begin inside small biotech companies, but how much those teams can discover is constrained by time, talent, and resources," said Sam Rodriques, Ph.D., founder and CEO of Edison Scientific. "Our goal is to use AI to dramatically expand what a biotech team can accomplish. If we get this right, we won't just build better companies, we'll build more of them, which means more shots on goal for patients waiting on new treatments."

About Edison Scientific

Edison Scientific is building the AI platform for scientific research and development. Kosmos, Edison’s collaborative AI scientist, partners with R&D teams to support critical decisions and workflows, leverage their proprietary data, and bring innovations to market faster. Edison is a scientist-led company that was spun out of the nonprofit research lab FutureHouse in 2025, backed by $70 million from Spark Capital, Triatomic Capital, and other investors. To learn more, visit edisonscientific.com and follow the company on LinkedIn and X.

About Population Health Partners

Population Health Partners is a global investor in people and technologies that generate healthspan and superior returns. Our portfolio includes Metsera, Corsera Health, Niroda Therapeutics, Onsera Health, and Civia Health. Each company is committed to fixing the biological and economic drivers of poor health at population scale. For more information, visit populationhp.com.

Media Contact

Nina Willdorf
nina@special-projects.io